JP2004504812A - 新規プロテアーゼ - Google Patents

Info

Publication number

JP2004504812A

JP2004504812A JP2001580389A JP2001580389A JP2004504812A JP 2004504812 A JP2004504812 A JP 2004504812A JP 2001580389 A JP2001580389 A JP 2001580389A JP 2001580389 A JP2001580389 A JP 2001580389A JP 2004504812 A JP2004504812 A JP 2004504812A

Authority

JP

Japan

Prior art keywords

seq

protease

sequence

polypeptide

nucleic acid

Prior art date

2000-05-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 108091005804 Peptidases Proteins 0.000 title claims abstract description 368
• 239000004365 Protease Substances 0.000 title claims abstract description 326
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract 22
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 284
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 257
• 229920001184 polypeptide Polymers 0.000 claims abstract description 242
• 238000000034 method Methods 0.000 claims abstract description 181
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 117
• 201000010099 disease Diseases 0.000 claims abstract description 87
• 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 44
• 238000011282 treatment Methods 0.000 claims abstract description 17
• 210000004027 cell Anatomy 0.000 claims description 214
• 150000007523 nucleic acids Chemical class 0.000 claims description 148
• 102000039446 nucleic acids Human genes 0.000 claims description 121
• 108020004707 nucleic acids Proteins 0.000 claims description 121
• 230000000694 effects Effects 0.000 claims description 81
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 79
• 230000027455 binding Effects 0.000 claims description 65
• 238000009739 binding Methods 0.000 claims description 64
• 239000002773 nucleotide Substances 0.000 claims description 56
• 125000003729 nucleotide group Chemical group 0.000 claims description 56
• 239000000523 sample Substances 0.000 claims description 55
• 238000003556 assay Methods 0.000 claims description 45
• 238000012360 testing method Methods 0.000 claims description 40
• 206010028980 Neoplasm Diseases 0.000 claims description 38
• 239000013598 vector Substances 0.000 claims description 31
• 210000001519 tissue Anatomy 0.000 claims description 30
• 239000000126 substance Substances 0.000 claims description 29
• 241000282414 Homo sapiens Species 0.000 claims description 28
• 208000035475 disorder Diseases 0.000 claims description 28
• 230000000295 complement effect Effects 0.000 claims description 27
• 239000012634 fragment Substances 0.000 claims description 26
• 238000009396 hybridization Methods 0.000 claims description 25
• 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 20
• 201000011510 cancer Diseases 0.000 claims description 20
• 239000002853 nucleic acid probe Substances 0.000 claims description 20
• 230000035897 transcription Effects 0.000 claims description 20
• 238000013518 transcription Methods 0.000 claims description 20
• 230000003993 interaction Effects 0.000 claims description 19
• 210000004556 brain Anatomy 0.000 claims description 18
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
• 241000124008 Mammalia Species 0.000 claims description 13
• 210000004408 hybridoma Anatomy 0.000 claims description 12
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 11
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 11
• 239000008280 blood Substances 0.000 claims description 11
• 230000001413 cellular effect Effects 0.000 claims description 11
• 230000009870 specific binding Effects 0.000 claims description 11
• 208000030159 metabolic disease Diseases 0.000 claims description 10
• 210000000481 breast Anatomy 0.000 claims description 9
• 206010020772 Hypertension Diseases 0.000 claims description 8
• 210000001072 colon Anatomy 0.000 claims description 8
• 210000004072 lung Anatomy 0.000 claims description 8
• 210000002307 prostate Anatomy 0.000 claims description 8
• 208000001953 Hypotension Diseases 0.000 claims description 7
• 208000019695 Migraine disease Diseases 0.000 claims description 7
• 208000019022 Mood disease Diseases 0.000 claims description 7
• 208000002193 Pain Diseases 0.000 claims description 7
• 208000028017 Psychotic disease Diseases 0.000 claims description 7
• 201000001880 Sexual dysfunction Diseases 0.000 claims description 7
• 210000000601 blood cell Anatomy 0.000 claims description 7
• 208000010877 cognitive disease Diseases 0.000 claims description 7
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 7
• 230000036543 hypotension Effects 0.000 claims description 7
• 208000027866 inflammatory disease Diseases 0.000 claims description 7
• 206010027599 migraine Diseases 0.000 claims description 7
• 210000002569 neuron Anatomy 0.000 claims description 7
• 231100000872 sexual dysfunction Toxicity 0.000 claims description 7
• 238000000338 in vitro Methods 0.000 claims description 6
• 208000027232 peripheral nervous system disease Diseases 0.000 claims description 6
• 208000028698 Cognitive impairment Diseases 0.000 claims description 5
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims description 3
• 208000037765 diseases and disorders Diseases 0.000 claims description 3
• 239000013642 negative control Substances 0.000 claims description 3
• 230000005856 abnormality Effects 0.000 claims description 2
• 238000012544 monitoring process Methods 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims 2
• 206010009944 Colon cancer Diseases 0.000 claims 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
• 206010033128 Ovarian cancer Diseases 0.000 claims 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
• 206010060862 Prostate cancer Diseases 0.000 claims 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
• 206010038389 Renal cancer Diseases 0.000 claims 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
• 208000015114 central nervous system disease Diseases 0.000 claims 2
• 201000010881 cervical cancer Diseases 0.000 claims 2
• 201000010982 kidney cancer Diseases 0.000 claims 2
• 201000005202 lung cancer Diseases 0.000 claims 2
• 208000020816 lung neoplasm Diseases 0.000 claims 2
• 230000002611 ovarian Effects 0.000 claims 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 179
• 102000004169 proteins and genes Human genes 0.000 abstract description 115
• 238000003745 diagnosis Methods 0.000 abstract description 2
• 102000035195 Peptidases Human genes 0.000 description 336
• 235000019419 proteases Nutrition 0.000 description 254
• 150000001875 compounds Chemical class 0.000 description 103
• 235000018102 proteins Nutrition 0.000 description 94
• 108020004414 DNA Proteins 0.000 description 55
• 230000014509 gene expression Effects 0.000 description 52
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 39
• 230000006870 function Effects 0.000 description 35
• 239000003446 ligand Substances 0.000 description 35
• 229940024606 amino acid Drugs 0.000 description 29
• 235000001014 amino acid Nutrition 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 29
• 102000004190 Enzymes Human genes 0.000 description 28
• 108090000790 Enzymes Proteins 0.000 description 28
• 229940088598 enzyme Drugs 0.000 description 28
• 235000019833 protease Nutrition 0.000 description 28
• 239000000203 mixture Substances 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 25
• 102000005741 Metalloproteases Human genes 0.000 description 24
• 108010006035 Metalloproteases Proteins 0.000 description 24
• 108091034117 Oligonucleotide Proteins 0.000 description 23
• 239000003814 drug Substances 0.000 description 23
• 238000012545 processing Methods 0.000 description 22
• 239000000243 solution Substances 0.000 description 22
• 230000003197 catalytic effect Effects 0.000 description 21
• 230000002159 abnormal effect Effects 0.000 description 20
• 108020004999 messenger RNA Proteins 0.000 description 20
• 239000000758 substrate Substances 0.000 description 19
• 102000005927 Cysteine Proteases Human genes 0.000 description 18
• 108010005843 Cysteine Proteases Proteins 0.000 description 18
• 239000002299 complementary DNA Substances 0.000 description 18
• 229940079593 drug Drugs 0.000 description 18
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 17
• 239000000047 product Substances 0.000 description 17
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 16
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 16
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 16
• 230000004913 activation Effects 0.000 description 16
• 230000000692 anti-sense effect Effects 0.000 description 16
• 208000024827 Alzheimer disease Diseases 0.000 description 15
• 239000003153 chemical reaction reagent Substances 0.000 description 15
• 238000012216 screening Methods 0.000 description 15
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 14
• 230000037361 pathway Effects 0.000 description 14
• 108090000994 Catalytic RNA Proteins 0.000 description 13
• 102000053642 Catalytic RNA Human genes 0.000 description 13
• 108020004705 Codon Proteins 0.000 description 13
• 108010050254 Presenilins Proteins 0.000 description 13
• 102000015499 Presenilins Human genes 0.000 description 13
• 239000000074 antisense oligonucleotide Substances 0.000 description 13
• 238000012230 antisense oligonucleotides Methods 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 239000000284 extract Substances 0.000 description 13
• 239000012528 membrane Substances 0.000 description 13
• 108091092562 ribozyme Proteins 0.000 description 13
• 238000013519 translation Methods 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• 230000001684 chronic effect Effects 0.000 description 12
• 239000003112 inhibitor Substances 0.000 description 12
• 238000004519 manufacturing process Methods 0.000 description 12
• 230000035772 mutation Effects 0.000 description 12
• 239000007787 solid Substances 0.000 description 12
• 238000012546 transfer Methods 0.000 description 12
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 11
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 238000003776 cleavage reaction Methods 0.000 description 11
• 238000005516 engineering process Methods 0.000 description 11
• 102000037865 fusion proteins Human genes 0.000 description 11
• 108020001507 fusion proteins Proteins 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 201000006417 multiple sclerosis Diseases 0.000 description 11
• 230000001105 regulatory effect Effects 0.000 description 11
• 230000007017 scission Effects 0.000 description 11
• 230000019491 signal transduction Effects 0.000 description 11
• 230000003612 virological effect Effects 0.000 description 11
• 102000004580 Aspartic Acid Proteases Human genes 0.000 description 10
• 108010017640 Aspartic Acid Proteases Proteins 0.000 description 10
• 201000001320 Atherosclerosis Diseases 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 238000001415 gene therapy Methods 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 230000001965 increasing effect Effects 0.000 description 10
• 239000002243 precursor Substances 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 230000009261 transgenic effect Effects 0.000 description 10
• 108091026890 Coding region Proteins 0.000 description 9
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 9
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
• -1 aspartyl Chemical group 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 239000003102 growth factor Substances 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 8
• 102000011727 Caspases Human genes 0.000 description 8
• 108010076667 Caspases Proteins 0.000 description 8
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 8
• 108010076504 Protein Sorting Signals Proteins 0.000 description 8
• 102000012479 Serine Proteases Human genes 0.000 description 8
• 108010022999 Serine Proteases Proteins 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 239000002585 base Substances 0.000 description 8
• 210000000349 chromosome Anatomy 0.000 description 8
• 238000010367 cloning Methods 0.000 description 8
• 230000015271 coagulation Effects 0.000 description 8
• 238000005345 coagulation Methods 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 238000001514 detection method Methods 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 239000013604 expression vector Substances 0.000 description 8
• 238000013537 high throughput screening Methods 0.000 description 8
• 230000004054 inflammatory process Effects 0.000 description 8
• 230000000977 initiatory effect Effects 0.000 description 8
• 230000004770 neurodegeneration Effects 0.000 description 8
• 208000015122 neurodegenerative disease Diseases 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 238000003752 polymerase chain reaction Methods 0.000 description 8
• 102000040430 polynucleotide Human genes 0.000 description 8
• 108091033319 polynucleotide Proteins 0.000 description 8
• 239000002157 polynucleotide Substances 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
• 241000894006 Bacteria Species 0.000 description 7
• 206010004146 Basal cell carcinoma Diseases 0.000 description 7
• 241000196324 Embryophyta Species 0.000 description 7
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 7
• 201000004681 Psoriasis Diseases 0.000 description 7
• 241000700605 Viruses Species 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 230000003321 amplification Effects 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 239000006184 cosolvent Substances 0.000 description 7
• 210000002744 extracellular matrix Anatomy 0.000 description 7
• 230000003834 intracellular effect Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 238000003199 nucleic acid amplification method Methods 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 108010032088 Calpain Proteins 0.000 description 6
• 102000007590 Calpain Human genes 0.000 description 6
• 108060005980 Collagenase Proteins 0.000 description 6
• 102000029816 Collagenase Human genes 0.000 description 6
• 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 6
• 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 6
• 102000005593 Endopeptidases Human genes 0.000 description 6
• 108010059378 Endopeptidases Proteins 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 244000060234 Gmelina philippensis Species 0.000 description 6
• 102000003693 Hedgehog Proteins Human genes 0.000 description 6
• 108090000031 Hedgehog Proteins Proteins 0.000 description 6
• 241000238631 Hexapoda Species 0.000 description 6
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
• 241000579835 Merops Species 0.000 description 6
• 208000018737 Parkinson disease Diseases 0.000 description 6
• 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 6
• 108700008625 Reporter Genes Proteins 0.000 description 6
• 108090000848 Ubiquitin Proteins 0.000 description 6
• 102000044159 Ubiquitin Human genes 0.000 description 6
• 208000036142 Viral infection Diseases 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 208000006673 asthma Diseases 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 210000000170 cell membrane Anatomy 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 206010012601 diabetes mellitus Diseases 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 230000002209 hydrophobic effect Effects 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 210000004962 mammalian cell Anatomy 0.000 description 6
• 229910052751 metal Inorganic materials 0.000 description 6
• 239000002184 metal Substances 0.000 description 6
• 229910021645 metal ion Inorganic materials 0.000 description 6
• 238000010369 molecular cloning Methods 0.000 description 6
• 229930014626 natural product Natural products 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 230000002797 proteolythic effect Effects 0.000 description 6
• 238000000746 purification Methods 0.000 description 6
• 206010039083 rhinitis Diseases 0.000 description 6
• 150000003839 salts Chemical class 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 241000701161 unidentified adenovirus Species 0.000 description 6
• 230000009385 viral infection Effects 0.000 description 6
• 108091007505 ADAM17 Proteins 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• 102000014914 Carrier Proteins Human genes 0.000 description 5
• 102100021633 Cathepsin B Human genes 0.000 description 5
• 206010011091 Coronary artery thrombosis Diseases 0.000 description 5
• 206010012218 Delirium Diseases 0.000 description 5
• 206010012289 Dementia Diseases 0.000 description 5
• 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 5
• 208000012661 Dyskinesia Diseases 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 208000031886 HIV Infections Diseases 0.000 description 5
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 5
• 208000023105 Huntington disease Diseases 0.000 description 5
• 102000001399 Kallikrein Human genes 0.000 description 5
• 108060005987 Kallikrein Proteins 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 102000043136 MAP kinase family Human genes 0.000 description 5
• 108091054455 MAP kinase family Proteins 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 208000025966 Neurological disease Diseases 0.000 description 5
• 208000008589 Obesity Diseases 0.000 description 5
• 108090000526 Papain Proteins 0.000 description 5
• 239000002202 Polyethylene glycol Substances 0.000 description 5
• 108091000054 Prion Proteins 0.000 description 5
• 102000029797 Prion Human genes 0.000 description 5
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
• 108090000783 Renin Proteins 0.000 description 5
• 102100028255 Renin Human genes 0.000 description 5
• 208000036623 Severe mental retardation Diseases 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• 208000000323 Tourette Syndrome Diseases 0.000 description 5
• 208000016620 Tourette disease Diseases 0.000 description 5
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 5
• 206010052779 Transplant rejections Diseases 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000033115 angiogenesis Effects 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 230000005784 autoimmunity Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 239000011230 binding agent Substances 0.000 description 5
• 108091008324 binding proteins Proteins 0.000 description 5
• 210000001124 body fluid Anatomy 0.000 description 5
• 239000010839 body fluid Substances 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 210000003679 cervix uteri Anatomy 0.000 description 5
• 229960002424 collagenase Drugs 0.000 description 5
• 230000001276 controlling effect Effects 0.000 description 5
• 208000002528 coronary thrombosis Diseases 0.000 description 5
• 210000002257 embryonic structure Anatomy 0.000 description 5
• 210000003527 eukaryotic cell Anatomy 0.000 description 5
• 230000002538 fungal effect Effects 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 208000037824 growth disorder Diseases 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
• 235000020824 obesity Nutrition 0.000 description 5
• 210000001672 ovary Anatomy 0.000 description 5
• 229940055729 papain Drugs 0.000 description 5
• 235000019834 papain Nutrition 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 229920003023 plastic Polymers 0.000 description 5
• 239000004033 plastic Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
• 210000001236 prokaryotic cell Anatomy 0.000 description 5
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 5
• 230000010410 reperfusion Effects 0.000 description 5
• 208000037803 restenosis Diseases 0.000 description 5
• 108091008146 restriction endonucleases Proteins 0.000 description 5
• 201000000980 schizophrenia Diseases 0.000 description 5
• 230000003248 secreting effect Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 230000005030 transcription termination Effects 0.000 description 5
• 210000003932 urinary bladder Anatomy 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
• 101710150192 Beta-secretase 1 Proteins 0.000 description 4
• 102000005367 Carboxypeptidases Human genes 0.000 description 4
• 108010006303 Carboxypeptidases Proteins 0.000 description 4
• 102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 4
• 230000004568 DNA-binding Effects 0.000 description 4
• 101800001224 Disintegrin Proteins 0.000 description 4
• 208000010412 Glaucoma Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• 208000022873 Ocular disease Diseases 0.000 description 4
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 4
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
• 102100038358 Prostate-specific antigen Human genes 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 208000017442 Retinal disease Diseases 0.000 description 4
• 206010038923 Retinopathy Diseases 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 241000187747 Streptomyces Species 0.000 description 4
• 108090000190 Thrombin Proteins 0.000 description 4
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 208000028683 bipolar I disease Diseases 0.000 description 4
• 210000002459 blastocyst Anatomy 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 230000036772 blood pressure Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 239000001506 calcium phosphate Substances 0.000 description 4
• 229910000389 calcium phosphate Inorganic materials 0.000 description 4
• 235000011010 calcium phosphates Nutrition 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000007876 drug discovery Methods 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 238000002955 isolation Methods 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000001161 mammalian embryo Anatomy 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 238000000520 microinjection Methods 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 210000004940 nucleus Anatomy 0.000 description 4
• 210000000578 peripheral nerve Anatomy 0.000 description 4
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 239000013600 plasmid vector Substances 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 238000000159 protein binding assay Methods 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000029865 regulation of blood pressure Effects 0.000 description 4
• 238000012552 review Methods 0.000 description 4
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• 229960004072 thrombin Drugs 0.000 description 4
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
• 238000010396 two-hybrid screening Methods 0.000 description 4
• 239000003981 vehicle Substances 0.000 description 4
• 239000013603 viral vector Substances 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 3
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 102000035101 Aspartic proteases Human genes 0.000 description 3
• 108091005502 Aspartic proteases Proteins 0.000 description 3
• 241000193830 Bacillus <bacterium> Species 0.000 description 3
• 102100021257 Beta-secretase 1 Human genes 0.000 description 3
• 208000020925 Bipolar disease Diseases 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 108090000712 Cathepsin B Proteins 0.000 description 3
• 102000004178 Cathepsin E Human genes 0.000 description 3
• 108090000611 Cathepsin E Proteins 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 238000009007 Diagnostic Kit Methods 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 241000282326 Felis catus Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 3
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
• 102100034681 Myeloblastin Human genes 0.000 description 3
• 108090000973 Myeloblastin Proteins 0.000 description 3
• 102000003729 Neprilysin Human genes 0.000 description 3
• 108090000028 Neprilysin Proteins 0.000 description 3
• 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 229920002684 Sepharose Polymers 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• 102000035100 Threonine proteases Human genes 0.000 description 3
• 108091005501 Threonine proteases Proteins 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 238000002820 assay format Methods 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000006555 catalytic reaction Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000002759 chromosomal effect Effects 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
• 239000008298 dragée Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 230000013020 embryo development Effects 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000001900 endoderm Anatomy 0.000 description 3
• 230000002255 enzymatic effect Effects 0.000 description 3
• 208000028653 esophageal adenocarcinoma Diseases 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 235000014304 histidine Nutrition 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 230000002132 lysosomal effect Effects 0.000 description 3
• 208000002780 macular degeneration Diseases 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 239000002858 neurotransmitter agent Substances 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000004844 protein turnover Effects 0.000 description 3
• 230000022983 regulation of cell cycle Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000000717 retained effect Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 230000007838 tissue remodeling Effects 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 2
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 2
• SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 2
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 108091022885 ADAM Proteins 0.000 description 2
• 102000029791 ADAM Human genes 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 206010002482 Angiosclerosis Diseases 0.000 description 2
• 102400000344 Angiotensin-1 Human genes 0.000 description 2
• 101800000734 Angiotensin-1 Proteins 0.000 description 2
• 102400000345 Angiotensin-2 Human genes 0.000 description 2
• 101800000733 Angiotensin-2 Proteins 0.000 description 2
• 102000004881 Angiotensinogen Human genes 0.000 description 2
• 108090001067 Angiotensinogen Proteins 0.000 description 2
• 108020004491 Antisense DNA Proteins 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108090000317 Chymotrypsin Proteins 0.000 description 2
• 101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 108090001081 Dipeptidases Proteins 0.000 description 2
• 102000004860 Dipeptidases Human genes 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 101710099240 Elastase-1 Proteins 0.000 description 2
• 241000701959 Escherichia virus Lambda Species 0.000 description 2
• 102000018389 Exopeptidases Human genes 0.000 description 2
• 108010091443 Exopeptidases Proteins 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
• 108090000402 Gamma-renin Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 2
• 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
• 241000709721 Hepatovirus A Species 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 2
• 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 102000003810 Interleukin-18 Human genes 0.000 description 2
• 108090000171 Interleukin-18 Proteins 0.000 description 2
• 108010044467 Isoenzymes Proteins 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 108010067372 Pancreatic elastase Proteins 0.000 description 2
• 102000016387 Pancreatic elastase Human genes 0.000 description 2
• 241000051107 Paraechinus aethiopicus Species 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 108090000113 Plasma Kallikrein Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102100034869 Plasma kallikrein Human genes 0.000 description 2
• 102100038124 Plasminogen Human genes 0.000 description 2
• 108010051456 Plasminogen Proteins 0.000 description 2
• 102000001938 Plasminogen Activators Human genes 0.000 description 2
• 108010001014 Plasminogen Activators Proteins 0.000 description 2
• 102100022036 Presenilin-2 Human genes 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 241000589516 Pseudomonas Species 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 208000034189 Sclerosis Diseases 0.000 description 2
• 102000008847 Serpin Human genes 0.000 description 2
• 108050000761 Serpin Proteins 0.000 description 2
• 238000002105 Southern blotting Methods 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 241000204667 Thermoplasma Species 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 102100034396 Trypsin-3 Human genes 0.000 description 2
• 206010064390 Tumour invasion Diseases 0.000 description 2
• 108010005705 Ubiquitinated Proteins Proteins 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 229960002478 aldosterone Drugs 0.000 description 2
• 125000001931 aliphatic group Chemical group 0.000 description 2
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
• ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
• 229950006323 angiotensin ii Drugs 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 230000002788 anti-peptide Effects 0.000 description 2
• 230000030741 antigen processing and presentation Effects 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 239000003816 antisense DNA Substances 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 239000003114 blood coagulation factor Substances 0.000 description 2
• 229940019700 blood coagulation factors Drugs 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000009400 cancer invasion Effects 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000006369 cell cycle progression Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000001612 chondrocyte Anatomy 0.000 description 2
• 229960002376 chymotrypsin Drugs 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229910017052 cobalt Inorganic materials 0.000 description 2
• 239000010941 cobalt Substances 0.000 description 2
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000007877 drug screening Methods 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 239000003792 electrolyte Substances 0.000 description 2
• 230000002121 endocytic effect Effects 0.000 description 2
• 229940066758 endopeptidases Drugs 0.000 description 2
• 210000001163 endosome Anatomy 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 210000003414 extremity Anatomy 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 229960005051 fluostigmine Drugs 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 108010067742 gamma nerve growth factor Proteins 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 210000004907 gland Anatomy 0.000 description 2
• 230000002414 glycolytic effect Effects 0.000 description 2
• 210000004349 growth plate Anatomy 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 238000010324 immunological assay Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000011005 laboratory method Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000004816 latex Substances 0.000 description 2
• 229920000126 latex Polymers 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229910052748 manganese Inorganic materials 0.000 description 2
• 239000011572 manganese Substances 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 210000000276 neural tube Anatomy 0.000 description 2
• 230000003472 neutralizing effect Effects 0.000 description 2
• 108091027963 non-coding RNA Proteins 0.000 description 2
• 102000042567 non-coding RNA Human genes 0.000 description 2
• 239000012038 nucleophile Substances 0.000 description 2
• 239000003791 organic solvent mixture Substances 0.000 description 2
• 230000011164 ossification Effects 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000001936 parietal effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 229940127126 plasminogen activator Drugs 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 239000004417 polycarbonate Substances 0.000 description 2
• 229920000515 polycarbonate Polymers 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 150000004804 polysaccharides Chemical class 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000013615 primer Substances 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 108010043524 protease E Proteins 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000006916 protein interaction Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000025915 regulation of apoptotic process Effects 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000002821 scintillation proximity assay Methods 0.000 description 2
• 210000000582 semen Anatomy 0.000 description 2
• 239000003001 serine protease inhibitor Substances 0.000 description 2
• 210000000717 sertoli cell Anatomy 0.000 description 2
• 230000007781 signaling event Effects 0.000 description 2
• 210000002356 skeleton Anatomy 0.000 description 2
• 210000002023 somite Anatomy 0.000 description 2
• 230000021595 spermatogenesis Effects 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 108091007196 stromelysin Proteins 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 150000007970 thio esters Chemical class 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000005026 transcription initiation Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 238000010798 ubiquitination Methods 0.000 description 2
• 230000034512 ubiquitination Effects 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• FRXCOWPKCBEBKD-JEDNCBNOSA-N (2S)-2-amino-4-methylpentanamide 2-butylguanidine Chemical compound CCCCN=C(N)N.CC(C)C[C@H](N)C(N)=O FRXCOWPKCBEBKD-JEDNCBNOSA-N 0.000 description 1
• CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• QXABAINQWXBUFW-UHFFFAOYSA-N 3-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxypropanoic acid Chemical compound OC(=O)C(O)CC1=CNC(=O)NC1=O QXABAINQWXBUFW-UHFFFAOYSA-N 0.000 description 1
• LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
• GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
• 102000043279 ADAM17 Human genes 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 108091005508 Acid proteases Proteins 0.000 description 1
• 229920000178 Acrylic resin Polymers 0.000 description 1
• 239000004925 Acrylic resin Substances 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 206010001488 Aggression Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 108091093088 Amplicon Proteins 0.000 description 1
• 108010087765 Antipain Proteins 0.000 description 1
• 241000256844 Apis mellifera Species 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 101150072353 CAPN3 gene Proteins 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
• 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
• 102100025172 Calpain-1 catalytic subunit Human genes 0.000 description 1
• 102100032537 Calpain-2 catalytic subunit Human genes 0.000 description 1
• 102100032539 Calpain-3 Human genes 0.000 description 1
• 102100030006 Calpain-5 Human genes 0.000 description 1
• 102100030005 Calpain-6 Human genes 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 241000710190 Cardiovirus Species 0.000 description 1
• 102100035904 Caspase-1 Human genes 0.000 description 1
• 108090000426 Caspase-1 Proteins 0.000 description 1
• 102000003902 Cathepsin C Human genes 0.000 description 1
• 108090000267 Cathepsin C Proteins 0.000 description 1
• 102100032219 Cathepsin D Human genes 0.000 description 1
• 108090000258 Cathepsin D Proteins 0.000 description 1
• 102100025975 Cathepsin G Human genes 0.000 description 1
• 108090000617 Cathepsin G Proteins 0.000 description 1
• 108090000625 Cathepsin K Proteins 0.000 description 1
• 102000004171 Cathepsin K Human genes 0.000 description 1
• 108090000613 Cathepsin S Proteins 0.000 description 1
• 102100035654 Cathepsin S Human genes 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 235000021538 Chard Nutrition 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
• 108020004394 Complementary RNA Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
• 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
• 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
• 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 102100031245 Disks large-associated protein 2 Human genes 0.000 description 1
• 108050003184 Disks large-associated protein 2 Proteins 0.000 description 1
• 108700010895 Drosophila ADH Proteins 0.000 description 1
• 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 1
• 206010013883 Dwarfism Diseases 0.000 description 1
• 108700033311 EC 3.4.23.16 Proteins 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 241000710188 Encephalomyocarditis virus Species 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108010014173 Factor X Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 101150082479 GAL gene Proteins 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000031995 Gorlin syndrome Diseases 0.000 description 1
• 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 101710176455 H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 108010043026 HGF activator Proteins 0.000 description 1
• 238000010268 HPLC based assay Methods 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000724675 Hepatitis E virus Species 0.000 description 1
• 102100031465 Hepatocyte growth factor activator Human genes 0.000 description 1
• 101000934069 Homo sapiens Calpain-1 catalytic subunit Proteins 0.000 description 1
• 101000867692 Homo sapiens Calpain-2 catalytic subunit Proteins 0.000 description 1
• 101000867715 Homo sapiens Calpain-3 Proteins 0.000 description 1
• 101000793666 Homo sapiens Calpain-5 Proteins 0.000 description 1
• 101000793671 Homo sapiens Calpain-6 Proteins 0.000 description 1
• 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
• 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
• 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
• 101000847952 Homo sapiens Trypsin-3 Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 102000004157 Hydrolases Human genes 0.000 description 1
• 108090000604 Hydrolases Proteins 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 108010093008 Kinins Proteins 0.000 description 1
• 102000002397 Kinins Human genes 0.000 description 1
• 102100020880 Kit ligand Human genes 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
• 101710117390 Mannan-binding lectin serine protease 1 Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
• 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 102000003843 Metalloendopeptidases Human genes 0.000 description 1
• 108090000131 Metalloendopeptidases Proteins 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 108060008487 Myosin Proteins 0.000 description 1
• 102000003505 Myosin Human genes 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• 108091008604 NGF receptors Proteins 0.000 description 1
• 108010012309 NS2-3 protease Proteins 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 108090000189 Neuropeptides Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108010070047 Notch Receptors Proteins 0.000 description 1
• 102000005650 Notch Receptors Human genes 0.000 description 1
• 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
• 201000000023 Osteosclerosis Diseases 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101150089079 PS1 gene Proteins 0.000 description 1
• 108010069873 Patched Receptors Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
• 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 229920002642 Polysorbate 65 Polymers 0.000 description 1
• 108010068086 Polyubiquitin Proteins 0.000 description 1
• 102100037935 Polyubiquitin-C Human genes 0.000 description 1
• 102100022033 Presenilin-1 Human genes 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
• 101710178372 Prolyl endopeptidase Proteins 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
• 101150040459 RAS gene Proteins 0.000 description 1
• 101150076031 RAS1 gene Proteins 0.000 description 1
• 108050006002 RNA polymerase sigma factor FliA Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 238000010240 RT-PCR analysis Methods 0.000 description 1
• 101000795023 Rattus norvegicus Trypsin-4 Proteins 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 102000000395 SH3 domains Human genes 0.000 description 1
• 108050008861 SH3 domains Proteins 0.000 description 1
• 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 101000721481 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Succinyl-diaminopimelate desuccinylase Proteins 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 102000003667 Serine Endopeptidases Human genes 0.000 description 1
• 108090000083 Serine Endopeptidases Proteins 0.000 description 1
• 102100032491 Serine protease 1 Human genes 0.000 description 1
• 101710151387 Serine protease 1 Proteins 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 208000020221 Short stature Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 241000251131 Sphyrna Species 0.000 description 1
• 108010039445 Stem Cell Factor Proteins 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
• 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 206010042573 Superovulation Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 101710097834 Thiol protease Proteins 0.000 description 1
• 102100036407 Thioredoxin Human genes 0.000 description 1
• LJJKNPQAGWVLDQ-UHFFFAOYSA-N Thiorphan Chemical compound OC(=O)CNC(=O)C(CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-UHFFFAOYSA-N 0.000 description 1
• 102000007983 Threonine endopeptidases Human genes 0.000 description 1
• 108030005531 Threonine endopeptidases Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 101710119665 Trypsin-1 Proteins 0.000 description 1
• 102100034392 Trypsin-2 Human genes 0.000 description 1
• 101710119666 Trypsin-2 Proteins 0.000 description 1
• 101710119642 Trypsin-3 Proteins 0.000 description 1
• 108060005989 Tryptase Proteins 0.000 description 1
• 102000001400 Tryptase Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
• 108010005656 Ubiquitin Thiolesterase Proteins 0.000 description 1
• 102100037587 Ubiquitin carboxyl-terminal hydrolase BAP1 Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 229910052770 Uranium Inorganic materials 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 108700010756 Viral Polyproteins Proteins 0.000 description 1
• 108700022715 Viral Proteases Proteins 0.000 description 1
• 101000752225 Xenopus laevis Low density lipoprotein receptor adapter protein 1-A Proteins 0.000 description 1
• 101710204001 Zinc metalloprotease Proteins 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• UUMKQZVEZSXWBY-HNNXBMFYSA-N [[(1s)-2-(4-phenylphenyl)-1-(2h-tetrazol-5-yl)ethyl]amino]methylphosphonic acid Chemical compound C([C@H](NCP(O)(=O)O)C1=NNN=N1)C(C=C1)=CC=C1C1=CC=CC=C1 UUMKQZVEZSXWBY-HNNXBMFYSA-N 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 229920006397 acrylic thermoplastic Polymers 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000007801 affinity label Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 239000012637 allosteric effector Substances 0.000 description 1
• 102000004139 alpha-Amylases Human genes 0.000 description 1
• 108090000637 alpha-Amylases Proteins 0.000 description 1
• 229940024171 alpha-amylase Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 108010052590 amastatin Proteins 0.000 description 1
• QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 description 1
• 150000001408 amides Chemical group 0.000 description 1
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229960004405 aprotinin Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 239000000305 astragalus gummifer gum Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 230000001908 autoinhibitory effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 239000013602 bacteriophage vector Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• YTIJUXVIZLYQTB-UHFFFAOYSA-N bethanidine sulfate Chemical compound [O-]S([O-])(=O)=O.CN\C(=[NH+]/C)NCC1=CC=CC=C1.CN\C(=[NH+]/C)NCC1=CC=CC=C1 YTIJUXVIZLYQTB-UHFFFAOYSA-N 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
• 102000036109 cAMP binding proteins Human genes 0.000 description 1
• 108091010966 cAMP binding proteins Proteins 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 201000011529 cardiovascular cancer Diseases 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 241000902900 cellular organisms Species 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000013377 clone selection method Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000006854 communication Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000536 complexating effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 235000021185 dessert Nutrition 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 235000021245 dietary protein Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• 108010083141 dipeptidyl carboxypeptidase Proteins 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 235000021186 dishes Nutrition 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 210000003981 ectoderm Anatomy 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000002848 electrochemical method Methods 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002242 embryoid body Anatomy 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 210000004212 embryonic organizer Anatomy 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000004039 endoderm cell Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
• 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
• 210000001097 facial muscle Anatomy 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 230000004129 fatty acid metabolism Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 235000019688 fish Nutrition 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000002875 fluorescence polarization Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 231100000221 frame shift mutation induction Toxicity 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 150000002402 hexoses Chemical class 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003317 immunochromatography Methods 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
• 229910001410 inorganic ion Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000010039 intracellular degradation Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 108010028930 invariant chain Proteins 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 101150109249 lacI gene Proteins 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000007347 lysosomal proteolysis Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000023508 male gonad development Effects 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 108010058731 nopaline synthase Proteins 0.000 description 1
• 210000003458 notochord Anatomy 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 238000000059 patterning Methods 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 125000004344 phenylpropyl group Chemical group 0.000 description 1
• 150000004633 phorbol derivatives Chemical class 0.000 description 1
• 239000002644 phorbol ester Substances 0.000 description 1
• RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
• 238000005375 photometry Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000008884 pinocytosis Effects 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229930001119 polyketide Natural products 0.000 description 1
• 125000000830 polyketide group Chemical group 0.000 description 1
• 229930001118 polyketide hybrid Natural products 0.000 description 1
• 125000003308 polyketide hybrid group Chemical group 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
• 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
• 108010000222 polyserine Proteins 0.000 description 1
• 229940099511 polysorbate 65 Drugs 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 108091005629 prenylated proteins Proteins 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 239000002987 primer (paints) Substances 0.000 description 1
• 108010029690 procollagenase Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 238000003614 protease activity assay Methods 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 101150079601 recA gene Proteins 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000008886 response to retinoic acid Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 230000009645 skeletal growth Effects 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000002689 soil Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 238000005507 spraying Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 150000003432 sterols Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 238000009495 sugar coating Methods 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 229920002994 synthetic fiber Polymers 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 238000012256 transgenic experiment Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000014599 transmission of virus Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 150000005691 triesters Chemical class 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 108010002164 tyrosine receptor Proteins 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 238000003158 yeast two-hybrid assay Methods 0.000 description 1
• 238000001086 yeast two-hybrid system Methods 0.000 description 1